未找到相关数据
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
被引：18
作者：
Ailawadhi, Sikander
Chanan-Khan, Asher Alban Akmal
Chen, Zi
Huang, Bo
Konopleva, Marina
Brander, Danielle M.
Rizzieri, David
Lasica, Masa
Tam, Constantine Si Lun
Yannakou, Costas K.
Prince, H. Miles
Davids, Matthew Steven
He, Zhicong
Lu, Ming
Ahmad, Mohammad
Li, Mingyu
Liang, Zhiyan
Mudenda, Boyd
Yang, Dajun
Zhai, Yifan
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[4] Duke Univ, Sch Med, Durham, NC USA
[5] St Vincents Hosp Sydney, Darlinghurst, NSW, Australia
[6] St Vincents Hosp, Melbourne, Vic, Australia
[7] Univ Melbourne, Melbourne, Vic, Australia
[8] Epworth HealthCare, Melbourne, Australia
[9] Peter MacCallum Canc Inst, Melbourne, Australia
[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[11] Jiangsu Ascentage Pharma Pty Ltd, Sydney, NSW, Australia
[12] Ascentage Pharma Grp Inc, Rockville, MD USA
[13] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.7502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7502
引用
收藏
页数：3
相关论文